Cheung Cheng - Sino Biopharmaceutica Executive Vice Chairlady of the Board

All Insiders . USA . 
Stock . Sino Biopharmaceutical Ltd . Stakeholders . Insider . Cheung Cheng
SBHMY Stock  USD 9.05  0.10  1.12%   

Executive

Ms. Cheng Cheung Ling serves as Executive Vice Chairlady of the Board of Sino Biopharmaceutical Ltd. Ms. Cheng graduated from the Guanghua School of Management of Peking University and obtained a Master Degree in Business Administration. She is a clinician since 2017.
Age 59
Tenure 7 years
Phone852 2802 9886
Webhttps://www.sinobiopharm.com
Cheng has extensive experience in and a discerning vision for management and investment in the pharmaceutical industry. She spares no effort in promoting innovation and R&D capabilities in the industry. She is the chairman of Beijing Tide. Being at the helm of Beijing Tide, Ms. Cheng advocates for innovations in R&D, production, sales, and management, and has led Beijing Tide to step up its efforts in developing international collaboration, with an aim to promote rapid development of cuttingedge technologies for medical products in China, and to give top priority to quality control, considering product quality as the lifeblood of the company. Under her leadership, Beijing Tide has achieved tremendous growth, riding on internationalization and innovation

Sino Biopharmaceutica Management Efficiency

The company has return on total asset (ROA) of 0.0451 % which means that it generated a profit of $0.0451 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2908 %, meaning that it generated $0.2908 on every $100 dollars invested by stockholders. Sino Biopharmaceutica's management efficiency ratios could be used to measure how well Sino Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.
Sino Biopharmaceutical Ltd has accumulated 5.21 B in total debt with debt to equity ratio (D/E) of 0.31, which is about average as compared to similar companies. Sino Biopharmaceutical has a current ratio of 1.52, which is within standard range for the sector. Debt can assist Sino Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Sino Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sino Biopharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sino to invest in growth at high rates of return. When we think about Sino Biopharmaceutica's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

MD MScVerastem
67
David SantosRigel Pharmaceuticals
61
Aron FeingoldGeron
N/A
Faye MDGeron
41
Michael CrowtherVerastem
N/A
Biren ShahElevation Oncology
N/A
Anil KapurGeron
54
Indira NaiduImmutep Ltd ADR
N/A
James MBAGeron
N/A
MSc BBAImmutep Ltd ADR
N/A
Edward KovalGeron
62
Robert YangElevation Oncology
N/A
Colleen MockbeeVerastem
N/A
Cathy CarewVerastem
N/A
Tarek SallamRigel Pharmaceuticals
N/A
Robert MBAVerastem
N/A
Candice MasseElevation Oncology
N/A
Julie PatelRigel Pharmaceuticals
N/A
John MDVerastem
47
MD MScImmutep Ltd ADR
N/A
Nate SanburnVerastem
N/A
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the Peoples Republic of China. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong. Sino Biopharmaceutica is traded on OTC Exchange in the United States. Sino Biopharmaceutical Ltd [SBHMY] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Return On Equity0.29
Return On Asset0.0451

Sino Biopharmaceutical Leadership Team

Elected by the shareholders, the Sino Biopharmaceutica's board of directors comprises two types of representatives: Sino Biopharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sino. The board's role is to monitor Sino Biopharmaceutica's management team and ensure that shareholders' interests are well served. Sino Biopharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sino Biopharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
Cheung Cheng, Executive Vice Chairlady of the Board
Fai Chia, Assistant to the President and Vice President
Wei Ye, Assistant President General Manager - R&D Department
Ping Tse, CEO, Executive Director
Mingqin Li, Vice President Executive Director
Wun Tse, Assistant to the President
Zhoushan Tian, Executive Director
Y Tse, Executive Chairlady of the Board
Hsin Tse, Vice President Executive Director
Eric Tse, CEO Director

Sino Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sino Biopharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.29
Return On Asset0.0451
Profit Margin0.29 %
Operating Margin0.16 %
Current Valuation10.34 B
Shares Outstanding940.69 M
Price To Earning8.95 X
Price To Book2.53 X
Price To Sales0.41 X
Revenue26.86 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C

Additional Tools for Sino Pink Sheet Analysis

When running Sino Biopharmaceutica's price analysis, check to measure Sino Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sino Biopharmaceutica is operating at the current time. Most of Sino Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Sino Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sino Biopharmaceutica's price. Additionally, you may evaluate how the addition of Sino Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY